Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Study Details
Study Description
Brief Summary
The purpose of this program is to provide access to tucatinib in the United States before FDA approval.
Participants will receive a combination treatment of capecitabine, trastuzumab, and tucatinib. All treatments will be given on a 21 day cycle.
To learn more about this program, contact Seattle Genetics' Medical Information (medinfo@seagen.com).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Have histologically confirmed HER2+ breast carcinoma, with HER2+ defined by ISH or FISH or IHC methodology
-
For patients WITHOUT presence or history of brain metastases, have received previous treatment with trastuzumab, pertuzumab, and T-DM1
-
For patients WITH presence or history of brain metastases, have received previous treatment with trastuzumab
-
Have progression of unresectable locally advanced or metastatic breast cancer after last systemic therapy (as confirmed by treating physician), or be intolerant of last systemic therapy
-
Have measurable disease or non-measurable disease assessable by standard of care imaging methods
-
Have ECOG PS 0 or 1
-
Have a life expectancy of at least 6 months, in the opinion of the treating physician
Exclusion Criteria:
-
Eligible for a tucatinib clinical trial
-
Disease recurrence within 3 months of last capecitabine for metastatic disease
-
History of allergic reactions to trastuzumab, capecitabine, or compounds chemically or biologically similar to tucatinib, except for Grade 1 or 2 infusion related reactions to trastuzumab that were successfully managed, or known allergy to one of the excipients in the protocol drugs
-
Have received treatment with any systemic anti-cancer therapy (excluding hormonal therapy), non-CNS radiation, or experimental agent ≤ 3 weeks of first dose of protocol treatment or are currently participating in an interventional clinical trial. Have received hormonal therapies <1 week of the first dose of protocol treatment.
-
Have any toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:
-
Alopecia and neuropathy, which must have resolved to ≤ Grade 2
-
CHF, which must have been ≤ Grade 1 in severity at the time of occurrence, and must have resolved completely
-
Anemia, which must have resolved to ≤ Grade 2
-
Have clinically significant cardiopulmonary disease
-
Have known myocardial infarction or unstable angina within 6 months prior to first dose of protocol treatment
-
Are known carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease with uncontrolled disease
-
Are known to be positive for HIV with uncontrolled disease
-
Are pregnant, breastfeeding, or planning a pregnancy
-
Require therapy with warfarin or other coumarin derivatives (non-coumarin anticoagulants are allowed)
-
Have inability to swallow pills or significant gastrointestinal disease which would preclude the adequate oral absorption of medications
-
Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a CYP2C8 or CYP3A4 inducer within 5 day prior to start of tucatinib treatment.
-
Have known dihydropyrimidine dehydrogenase deficiency
-
Have evidence within 2 years of the start of protocol treatment of another malignancy that required systemic treatment.
CNS Exclusion - patients must not have any of the following:
-
Any untreated brain lesions > 2.0 cm in size, unless discussed with medical monitor and approval for enrollment is given
-
Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent). However, patients on a chronic stable dose of ≤ 2 mg total daily of dexamethasone (or equivalent) may be eligible with discussion and approval by the medical monitor
-
Any brain lesion thought to require immediate local therapy, including (but not limited to) a lesion in an anatomic site where increase in size or possible treatment-related edema may pose risk to patient (e.g. brain stem lesions).
-
Known or suspected LMD as documented by the treating physician
-
Have poorly controlled (> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain metastases notwithstanding CNS-directed therapy
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Seagen Inc.
- Parexel
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SGNTUC-021